'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Lupin has increased 14.24% to Rs 5667.13 crore. Sales of Pharmaceuticals segment has gone up 14.05% to Rs 5,636.11 crore (accounting for 99.44% of total sales). Sales of others segment has gone up 55.85% to Rs 31.56 crore (accounting for 0.56% of total sales). Inter-segment sales came down from Rs 1.21 crore to Rs 0.54 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 79.99% to Rs 895.84 crore. PBIT of Pharmaceuticals segment rose 74.46% to Rs 932.20 crore (accounting for 104.06% of total PBIT). PBIT of others segment rose 0.74% to Rs -36.36 crore (accounting for -4.06% of total PBIT).
PBIT margin of Pharmaceuticals segment rose from 10.81% to 16.54%. PBIT margin of others segment rose from nega...
Pleaselogin & subscribe to view the full report.
More Reports
|
|